On Invalid Date, Lava Therapeutics Nv (NASDAQ: LVTX) reported Q4 2023 earnings per share (EPS) of -$0.24, up 59.74% year over year. Total Lava Therapeutics Nv earnings for the quarter were -$7.22 million. In the same quarter last year, Lava Therapeutics Nv's earnings per share (EPS) was -$0.61.
As of Q2 2024, Lava Therapeutics Nv's earnings has grown year over year. Lava Therapeutics Nv's earnings in the past year totalled -$45.62 million.
What is LVTX's earnings date?
Lava Therapeutics Nv's earnings date is Invalid Date. Add LVTX to your watchlist to be reminded of LVTX's next earnings announcement.
What was LVTX's revenue last quarter?
On Invalid Date, Lava Therapeutics Nv (NASDAQ: LVTX) reported Q4 2023 revenue of $392.22 thousand up 86.03% year over year. In the same quarter last year, Lava Therapeutics Nv's revenue was $2.81 million.
What was LVTX's revenue growth in the past year?
As of Q2 2024, Lava Therapeutics Nv's revenue has grown -63.54% year over year. This is 209.27 percentage points lower than the US Biotechnology industry revenue growth rate of 145.73%. Lava Therapeutics Nv's revenue in the past year totalled $7.36 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.